A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants
Latest Information Update: 28 Aug 2025
At a glance
- Drugs LY 4066708 (Primary) ; LY 4066708 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 09 Jul 2025 New trial record